文献速递心脏核医学放射性药物与辐射防护

未满足的临床需求:血栓成像的历史

An unmet clinical need: The history of thrombus imaging.
PubMed 文献 · J Nucl Cardiol · 2017-06-12

血栓成像是自20世纪70年代中期以来尚未解决的临床未满足需求。早期分子成像始于核医学SPECT,几乎所有生物医学成像模态的对比剂均已在体内验证,各有优势与共同弱点。血栓成像主要靶向血小板和纤维蛋白;急性血栓易于成像,但陈旧血栓仍是挑战,抗凝治疗持续干扰并常抵消血栓成像效果。

要点

  • 血栓成像是自20世纪70年代中期以来未解决的临床未满足需求。
  • 急性血栓易于成像,但陈旧血栓仍是挑战。
  • 抗凝治疗持续干扰并常抵消血栓成像效果,但肺栓塞、深静脉血栓或冠状动脉破裂斑块疑似患者在确诊检查前临床需要肝素。

核心结论

  • 血栓成像仍是未解决的临床未满足需求,这些根本问题可以克服,但需要创新性偏离既往方法。

研究设计与样本

  • 原文为历史回顾性叙述,未报告系统检索范围、样本量或研究设计细节。

主要发现

  • 早期分子成像始于核医学SPECT成像,几乎所有生物医学成像模态的对比剂均已在体内验证,各有独特优势和共同弱点。
  • 血栓成像主要 pursued 两个分子靶点:血小板和纤维蛋白。
  • 急性血栓易于用所有探针和模态成像,但陈旧血栓仍是挑战。
  • 抗凝治疗持续干扰并常抵消血栓成像效果,但肺栓塞、深静脉血栓或冠状动脉破裂斑块疑似患者在确诊诊断检查执行和解读前临床需要肝素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Robust thrombus imaging is an unresolved clinical unmet need dating back to the mid 1970s. While early molecular imaging approaches began with nuclear SPECT imaging, contrast agents for virtually all biomedical imaging modalities have been demonstrated in vivo with unique strengths and common weaknesses. Two primary molecular imaging targets have been pursued for thrombus imaging: platelets and fibrin. Some common issues noted over 40 years ago persist today. Acute thrombus is readily imaged with all probes and modalities, but aged thrombus remains a challenge. Similarly, anti-coagulation continues to interfere with and often negate thrombus imaging efficacy, but heparin is clinically required in patients suspected of pulmonary embolism, deep venous thrombosis or coronary ruptured plaque prior to confirmatory diagnostic studies have been executed and interpreted. These fundamental issues can be overcome, but an innovative departure from the prior approaches will be needed.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Lanza GM, Cui G, Schmieder AH, et al. An unmet clinical need: The history of thrombus imaging. J Nucl Cardiol. 2017. PMID: 28608182. doi:10.1007/s12350-017-0942-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。